Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease
- 294 Downloads
MAO-B and COMT are both enzymes involved in dopamine breakdown and metabolism. Inhibitors of these enzymes are used in the treatment of Parkinson’s disease. This review article describes the scientific background to the localization and function of the enzymes, the physiological changes resulting from their inhibition, and the basic and clinical pharmacology of the various inhibitors and their role in treatment of Parkinson’s disease.
KeywordsMAO-B COMT l-DOPA Dopamine synthesis Dyskinesia
Compliance with ethical standards
Conflict of interest
The author was a developer of rasagiline and receives royalties from the sale of this drug. This financial connection with the pharmaceutical industry in no way affected his opinions in writing this article.
- Finberg JP, Gillman PK (2011) Selective inhibitors of monoamine oxidase type B and the “cheese effect”. In: Youdim MB, Riederer P (eds) International review of neurobiology, vol 100. Academic Press, Burlington, pp 169–190Google Scholar
- Kuoppamaki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J et al (2009) Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 65(5):443–455CrossRefPubMedGoogle Scholar
- Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78(4):727–735CrossRefPubMedGoogle Scholar
- Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947–954CrossRefPubMedGoogle Scholar
- Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW et al (2011) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 10(5):415–423CrossRefPubMedGoogle Scholar
- Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R et al (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763–775CrossRefPubMedPubMedCentralGoogle Scholar
- Rocha JF, Ferreira JJ, Falcao A, Santos A, Pinto R, Nunes T et al (2016) Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with parkinson disease. Clin Pharmacol Drug Dev 5(3):232–240CrossRefPubMedGoogle Scholar
- Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P et al (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51(5):604–612CrossRefPubMedGoogle Scholar
- Vaya J, Aluf Y, Finberg JPM (2012) Oxidative stress in Parkinson’s disease. In: Gadoth N, Gobel HH (eds) Oxidative stress and free radical damage in neurology. Springer, New York, pp 191–224Google Scholar